Lupin Ltd has received tentative approval from the USFDA for its generic enzalutamide tablets used to treat castration-resistant prostate cancer. The approval covers four dosage strengths, including 120 mg and 160 mg variants, offering healthcare providers and patients more dosing options
KIMS Hospitals, Hyderabad, successfully treated 13 patients, including three foreign nationals, for localized prostate cancer and enlargement using the Tulsa-Pro system — Southeast Asia’s first MRI-guided, incision-less day-care procedure launched by CMD Dr B Bhaskar Rao
